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ABSTRACT
The realization of the therapeutic potential of targeting the M1
muscarinic acetylcholine receptor (mAChR) for the treatment
of cognitive decline in Alzheimer’s disease has prompted the
discovery of M1 mAChR ligands showing efficacy in alleviating
cognitive dysfunction in both rodents and humans. Among these
is GSK1034702 (7-fluoro-5-methyl-3-[1-(oxan-4-yl)piperidin-4-
yl]-1H-benzimidazol-2-one), described previously as a potentM1
receptor allosteric agonist, which showed procognitive effects in
rodents and improved immediate memory in a clinical nicotine
withdrawal test but induced significant side effects. Here we
provide evidence using ligand binding, chemical biology and
functional assays to establish that rather than the allosteric
mechanism claimed, GSK1034702 interacts in a bitopic manner
at the M1 mAChR such that it can concomitantly span both
the orthosteric and an allosteric binding site. The bitopic
nature of GSK1034702, together with the intrinsic agonist
activity and a lack of muscarinic receptor subtype selectivity
reported here, all likely contribute to the adverse effects of
this molecule in clinical trials. Although they impart beneficial
effects on learning and memory, we conclude that these
properties are undesirable in a clinical candidate due to the
likelihood of adverse side effects. Rather, our data support
the notion that “pure” positive allosteric modulators showing
selectivity for the M1 mAChR with low levels of intrinsic
activity would be preferable to provide clinical efficacy with
low adverse responses.
Introduction
The M1 muscarinic acetylcholine receptor (mAChR) has
emerged as an attractive molecular target to overcome cogni-
tive decline associated with cholinergic degeneration in Alz-
heimer disease (AD) (Anagnostaras et al., 2003). Activation of
M1mAChRs, which are abundantly expressed in the amygdala,
cerebral cortex, striatum, and hippocampus (Buckley et al.,
1988; Levey et al., 1995), has been reported to rescue learning
and memory deficits associated with neurodegeneration in a
number of mouse models (Lange et al., 2015; Puri et al., 2015;
Vardigan et al., 2015; Bradley et al., 2017). Translating these
promising findings to successful clinical candidates has,
however, been challenging due to adverse effects associated
with a lack of selectivity of orthosteric M1 mAChR agonists.
This is exemplified by the M1/M4-preferring mAChR agonist
xanomeline, which significantly improved cognitive function
in patients with AD (Bodick et al., 1997) but ultimately failed
due to adverse effects attributed to activation of peripheral
cholinergic signaling likely through M2 and M3 mAChRs
(Langmead et al., 2008).
There is, therefore, an urgent need to develop novel approaches
to build selectivity into M1 mAChR ligands. Two related ap-
proaches to this problem have been taken: 1) the development of
positive allosteric modulators (PAMs) that bind to a site that is
topographically distinct from that of the endogenous ligand
acetylcholine (ACh) (May et al., 2007) and 2) development of a
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newer generation of more selective agonists (whosemechanism
of action is not always well defined) (Langmead et al., 2008).
Allosteric modulators enhance ACh binding and/or signaling,
the magnitude of which can vary with different degrees
of positive cooperativity (Langmead and Christopoulos, 2006;
May et al., 2007; Conn et al., 2009). They can also possess
direct allosteric agonist activity (intrinsic activity). M1 mAChR
allosteric modulators with high functional selectivity over other
muscarinic receptor subtypes (i.e., M2–M5 mAChRs) have been
reported to reverse phenotypes associated with neurodegener-
ative disease (Ma et al., 2009; Puri et al., 2015; Vardigan et al.,
2015; Bradley et al., 2017) while showing no adverse side effects
in animal models (Bradley et al., 2017).
Less well described in the literature is the development of a
new generation of M1 mAChR agonists, which have variously
been described as “ectopic” (Spalding et al., 2002), “allosteric”
(Langmead and Christopoulos, 2006; Jones et al., 2008;
Budzik et al., 2010), “atypical” (Lebon et al., 2009), and
“bitopic” (Keov et al., 2011). With but a few exceptions (Keov
et al., 2014), this broad nomenclature reflects a paucity in
understanding of mechanism(s) of action; it is not clear
whether some of these ligands exert true allosteric agonism
(i.e., bind solely to an allosteric binding site to activate the
receptor), are subtype-selective orthosteric agonists, or repre-
sent a hybrid of the two (with a pharmacophore that engages
both orthosteric and allosteric binding pockets).
GSK1034702 (7-fluoro-5-methyl-3-[1-(oxan-4-yl)piperidin-
4-yl]-1H-benzimidazol-2-one) has been described as an allo-
steric M1 mAChR agonist; it was identified from a series of
benzimidazolones and reversed scopolamine-induced amnesia
in rodents (Budzik et al., 2010) and had positive effects on
cognitive function in humans. Unfortunately, it also induced
gastrointestinal adverse effects, consistent with activation of
peripheral mAChRs (Nathan et al., 2013).
Here we conduct a comprehensive pharmacological anal-
ysis of GSK1034702 and show that this molecule is not a
purely allosteric ligand as previously suggested. Radio-
ligand binding, using [3H]-N-methylscopolamine (NMS) and
[3H]-GSK1034702, and functional inositol phosphate (IP)
accumulation studies at the muscarinic M1 receptor reveal
that GSK1034702 interacts with the orthosteric ACh binding
site and likely, concomitantly, with an allosteric binding site.
Importantly, this bitopic mode of action is able to mediate
beneficial effects on learning andmemory but the lower degree
of selectivity of GSK1034702 compared with ligands that
engage solely with an allosteric binding site, together with
Fig. 1. (A–C) Effects of xanomeline (1, 3, 10, and 30 mg/kg) (A), GSK1034702 (0.3, 1, 3, 10, and 30 mg/kg) (B), and TBPB (1, 3, 10, and 30 mg/kg) (C) on
scopolamine (1.5mg/kg)–induced impairments in contextual fear conditioning (inset chemical structures of compounds). Data are expressed as themeans
6S.E.M. of eight ormoremice per group. Datawere analyzed using a one-way analysis of variance with the Tukeymultiple comparison test. *P, 0.05; **
P, 0.01; ***P, 0.001 vs. vehicle alone; #P, 0.05 vs. 1.5mg/kg scopolamine. (D–F)Unbound concentrations (LogM) of xanomeline (D), GSK1034702 (E),
and TBPB (F) measured in plasma or brain samples 30 minutes after intraperitoneal injection with increasing concentrations of respective compound.
Data are expressed as the means 6 S.E.M. of three mice per concentration.
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the intrinsic agonist activity reported here, may account for
the adverse effects observed with this molecule in the clinic.
Materials and Methods
Materials. GSK1034702 and xanomeline were synthesized by
Eli Lilly (Windlesham, Surrey, UK). IP-One and extracellular
signal–regulated kinase 1/2 (ERK1/2) phosphorylation assay kits
were purchased from Cisbio Assays (Codolet, France). TBPB (1-[19-(2-
methylbenzyl)-1,49-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-
2-one) was obtained from Tocris Bioscience (Bristol, UK). All other
chemicals and reagents were purchased from Sigma-Aldrich Com-
pany Ltd. (Dorset, UK).
Mouse Maintenance and Diet. All experiments were per-
formed under a project license from the British Home Office (United
Kingdom) under the Animals (Scientific Procedures) Act of 1986.
C57Bl/6J mice used in this study were purchased from Charles
River (Margate, UK). Mice were fed ad libitum with a standard
mouse chow and were maintained within the animal facility at least
1 week prior to experiments.
Fear Conditioning. C57Bl/6J male mice (aged 8–12 weeks) were
acclimatized to the behavioral testing suite at least 2 hours prior to the
test. Mice were injected (intraperitoneally) with vehicle (5% glucose)
or scopolamine (1.5 mg/kg) alone or in combination with xanomeline,
GSK1034702, or TBPB 30minutes prior to training. Mice were placed
in the conditioning chamber (ANY-maze Fear Conditioning System;
Stoelting, Dublin, Ireland); after a 2-minute adaptation period, they
received three tone/foot shock pairings where the foot shock (un-
conditioned stimulus; 2 seconds; 0.4 mA) always co-terminated with a
tone (conditioned stimulus; 2.8 kH; 85 dB; 30 seconds). The condi-
tioned stimulus–unconditioned stimulus pairings were separated by
1-minute intervals. After the mice completed training, they remained
in the conditioning chamber for 1 minute and were then returned to
their home cages. The next day, the mice were placed back in the
conditioning chamber, and time spent immobile was recorded for
3 minutes to assess context-dependent learning. Data were analyzed
using ANY-maze software (Stoelting).
Mouse Pharmacokinetics. Pharmacokinetic analyses were con-
ducted as previously described (Witkin et al., 2017). Compounds were
administered via intraperitoneal injection (in 5% glucose) 30 minutes
prior to blood collection. Mice were anesthetized with 3% isoflurane
(2 l/min), and blood was collected by cardiac puncture of the left
ventricle. Blood was immediately transferred to EDTA tubes and
centrifuged at 1000g for 10 minutes at 4°C; the supernatant was
collected and frozen. Brains from each mouse were also dissected and
snap-frozen on dry ice.
Brain sampleswerehomogenized in threevolumes ofmethanol/water
[1:4 (v/v)] by weight. A 25-ml aliquot of each study sample, calibration
standard, and control sample was added to a 96-well plate and mixed
with 180 ml acetonitrile/methanol [1:1 (v/v)] containing internal stan-
dard. The samples were subsequently centrifuged, and the resulting
supernatants were diluted 12.5-fold with methanol/water [1:1 (v/v)]
prior to analyzing 10-ml aliquots by liquid chromatography–tandem
mass spectrometry as previously described (Bradley et al., 2017).
Equilibrium [3H]-NMS Binding. Chinese hamster ovary (CHO)
Flp-In cells expressing the wild-typeM1mAChR (Bmax5 870 fmol/mg)
or the M1 designer receptor exclusively activated by designer drug
(DREADD) (Bmax 5 2400 fmol/mg) were plated at 7500 cells/well in
clear 96-well plates and grown to confluence. Prior to the experiment,
cells were washed with 100 ml phosphate-buffered saline. Increasing
concentrations of test compounds and an approximate equilibrium
dissociation constant (KD) concentration of [
3H]-NMS (KD (nM) for
[3H]-NMS binding to CHO Flp-In cells expressing wild-type M1
mAChR or M1 DREADD were 0.37 6 0.10 and 18.70 6 3.49 (n 5 3)
were incubated with cells overnight at room temperature in a final
volume of 100 ml binding buffer of the following composition: 110 mM
NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 1 mM MgSO4, 25 mM glucose,
20 mM HEPES, and 58 mM sucrose, pH 7.4. Binding was terminated
by rapid aspiration followed by two washes with 200 ml ice-cold 0.9%
NaCl. Bound radioactivity was determined by liquid scintillation
(Ultima Gold; PerkinElmer, Boston, MA) counting. Nonspecific bind-
ing was determined in the presence of 10 mM atropine.
For competition binding experiments at M1, M2, M3, M4, and M5
mAChRs, CHO membranes were purchased from PerkinElmer. All
experiments were performed in assay buffer of the following compo-
sition: 20 mM HEPES, 100 mMNaCl, and 10 mMMgCl2, pH 7.5, and
used 10 mg protein/well in a total assay volume of 1 ml using deep well
blocks. CHO cell membranes overexpressing human mAChR M1–M5
subtypes were incubated with a concentration of [3H]-NMS that was
close to the calculatedKD for each receptor (M1: 200 pM,KD5 196 pM;
M2: 700 pM, KD5 769 pM; M3: 700 pM, KD5 642 pM; M4: 200 pM, KD
143 pM; M5: 400 pM, KD 5 410 pM), in the presence or absence of
11 different concentrations of compound. Nonspecific binding was
determined in the presence of 10 mM atropine. All assay incubations
were initiated by the addition of membrane suspensions and deep
well blocks were shaken for 5 minutes to ensure complete mixing.
Incubation was then carried out for 2 hours at 21°C. Binding
reactions were terminated by rapid filtration through GF/A filters
(PerkinElmer) presoaked with 0.5% (w/v) polyethylenimine for
1 hour. Filters were then washed three times with 1 ml ice-cold
assay buffer. Dried filters were counted with Meltilex A scintillant
using a Trilux 1450 scintillation counter (PerkinElmer). The specific
bound counts (in disintegrations per minute) were expressed as a
percentage of the maximal binding observed in the absence of test
compound (total) and nonspecific binding determined in the pres-
ence of 10 mM atropine.
Kinetic [3H]-NMS Binding. For determination of [3H]-NMS
dissociation kinetics, membranes (5 mg/tube) expressing the M1
mAChR were preincubated with [3H]-NMS for 1 hour at 37°C in
binding buffer containing 100 mM NaCl, 10 mM MgCl2, and 20 mM
HEPES, pH 7.4. Dissociation of the bound radioligand was initiated
Fig. 2. Displacement of [3H]-NMS binding by ACh, xanomeline,
GSK1034702, or TBPB at the human M1 mAChR expressed in CHO
Flp-In cell monolayers. Experiments were performed against a KD
concentration of [3H]-NMS. Nonspecific binding was determined by the
addition of 10 mM atropine. Data are expressed as the means 6 S.E.M. of
three to five independent experiments performed in duplicate.
TABLE 1
Affinity estimates for the competition between [3H]-NMS and ACh,
xanomeline, GSK1034702, or TBPB at the M1 mAChR
Values stated are the negative logarithms of the equilibrium dissociation constant
(pKi). Data are calculated from the means 6 S.E.M. of three to five independent
experiments performed in duplicate.
Compound pKi n
ACh 4.1 6 0.3 5
Xanomeline 7.0 6 0.1 4
GSK1034702 6.5 6 0.2 3
TBPB 6.8 6 0.1 3
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by the addition of atropine (10 mM) alone or atropine (10 mM) plus
100 mM GSK1034702 added in a reverse time course protocol.
Reactions were terminated by rapid filtration onto GF/B filter paper
(Whatman, Maidstone, UK) and three washes with 3 ml ice-cold 0.9%
NaCl using a Brandel harvester (M-24TI; Brandel, Fort Lauderdale,
FL). Membrane bound radioactivity was determined by liquid
scintillation (Ultima Gold; PerkinElmer) counting.
IP-One Accumulation Assay. Stimulation of IP accumulation was
determined using the Cisbio IP-One Gq assay kit per the manufacturer’s
instructions. For agonist concentration-response curves, agonists (2
concentrated) were added to 384-well white ProxiPlates (PerkinElmer)
in 7 ml stimulation buffer. CHO Flp-In cells stably expressing the human
M1 mAChR were grown to confluence in T75 cell culture flasks at 37°C.
Cells were washed with warm phosphate-buffered saline and detached
using phosphate-buffered saline with 0.1 M EDTA. Detached cells were
centrifuged at 1000g and the cells were resuspended in stimulation buffer.
Sevenmicroliters of this cell suspension (1.43 106 cells/ml) was added to
each well, and cells were stimulated for 45 minutes at 37°C.
For functional interaction studies, CHO Flp-In cells stably express-
ing the human M1 mAChR were seeded at 5000 cells/well in 384-well
white ProxiPlates. Experiments were conducted 48 hours later. Cells
were washed once with 50 ml phosphate-buffered saline and then
incubated in F12 media containing phenoxybenzamine (where appli-
cable) at 37°C for 30minutes. Cellswerewashedwith 50ml phosphate-
buffered saline and incubated in stimulation buffer containing
agonists in a final volume of 14 ml for 45 minutes at 37°C.
All IP-One stimulationswere terminated by the addition of 3ml/well
IP1-d2 solution, followed by 3 ml/well anti–IP1-cryptate solution and
incubation for 1 hour at room temperature with shaking. Fluorescence
emission at two different wavelengths (665 and 620 nm) was
measured with a PHERAstar plate reader (BMG Labtech, Ortenberg,
Germany).
ERK1/2 Phosphorylation. Stimulation of phospho-ERK1/2 (Thr
202/Tyr 204) was determined using the Cisbio Phospho-ERK Cellular
Assay Kit. CHO Flp-In cells stably expressing the humanM1 receptor
were seeded onto transparent 96-well plates at 20,000 cells/well and
grown to confluence. Cells were serum starved overnight prior to the
experiment. Prior to the stimulations, cells were washed with 100 ml
phosphate-buffered saline and then incubated in serum free F12
medium at 37°C. Cells were stimulated with ligands for 5 minutes at
37°C in a final volume of 200 ml. The stimulations were terminated by
rapid aspiration and addition of 50 ml lysis buffer supplemented with
blocking reagent per the manufacturer’s instructions, followed by
gentle agitation at room temperature for 30 minutes. Subsequently,
16 ml of this lysate was transferred to a 384-well white ProxiPlate
(PerkinElmer) and incubated with 4 ml premixed antibody solution for
2 hours at room temperature. Fluorescence emission at two different
wavelengths (665 and 620 nm)wasmeasuredwith a PHERAstar plate
reader (BMG Labtech).
Native Tissue GTPɣ[35S] Binding Assays. GTPɣ-[35S] ([35S]ɣ
[guanosine-59-O-(3-[35S]thio)triphosphate] binding in rat membranes was
determined in triplicate using an antibody capture technique in 96-well
plate format (DeLapp et al., 1999). Native ratmembraneswere prepared
as follows.All procedureswere performedat 4°C.Ten to fifteenmilliliters
of sucrose buffer (10mMHEPES, 1mMEGTA, 1mMdithiothreitol, 10%
sucrose, and one tablet/50 ml Complete Protease Inhibitor Cocktail, pH
7.4) was added to each tissue sample and homogenized for 10 strokes
using an electric IKA RW20 homogenizer (800 rpm) (IKA, Staufen,
Germany) with glass homogenizer. The homogenate was centrifuged at
1000g for 10 minutes at 4°C and the supernatant collected. The pellet
was rehomogenized and centrifuged again as above and the supernatant
pooled and centrifuged at 11,000g for 20 minutes at 4°C. The resulting
pellet was suspended in40ml final storage buffer (10mMHEPES, 1mM
EGTA, 1mMMgCl2, and 1mMdithiothreitol, pH 7.4) and centrifuged at
27,000g for 20 minutes at 4°C. The supernatant was removed and the
final pellet was suspended in 2 ml final storage buffer. The protein
concentration was measured using the Bradford method (Coomassie
Plus, Bio-Rad protein assay kit; Bio-Rad, Hercules, CA) with bovine
gamma globulin standards. Samples were aliquoted and stored
at 280°C. Membrane aliquots (15 mg/well) were then incubated with
test compound and GTPɣ[35S] (500 pM/well) for 30 minutes. Labeled
membranes were then solubilized with 0.27% Nonidet P-40 plus Gqa
antibody (E17; Santa Cruz Biotechnology, Dallas, TX) at a final
dilution of 1:200 and 1.25 mg/well anti-rabbit scintillation proximity
beads. Plates were left to incubate for 3 hours and then centrifuged
for 10 minutes at 2000 rpm. Plates were counted for 1 minute/well
using a Wallac MicroBeta Trilux scintillation counter (Perki-
nElmer). All incubations took place at room temperature in GTP-
binding assay buffer of the following composition: 20 mM HEPES,
100 mM NaCl, and 5 mMMgCl2, pH 7.5. Data were converted to the
percentage of response compared with oxotremorine-M (100 mM) or
the percentage over basal and EC50 values were generated (four-
parameter logistic curve) using GraphPad Prism 6 software (Graph-
Pad Software Inc., La Jolla, CA).
Fig. 3. (A and B) Dissociation of [3H]-NMS with
atropine in the absence or presence of GSK1034702
(A) or TBPB (B) inmembranes expressing the human
M1 receptor. Membranes were incubated with a KD
concentration of [3H]-NMS for 60 minutes at 37°C,
followed by dissociation of bound radioligand with
atropine (10 mM) alone or in the presence of
GSK1034702 (10 mM) or TBPB (10 mM). Data shown
are the mean of three independent experiments
performed in duplicate.
Fig. 4. (A) IP accumulation elicited by ACh, xano-
meline, GSK1034702, or TBPB via the human M1
receptor expressed in CHO Flp-In cells. Data are
expressed as the means 6 S.E.M. of 3–10 indepen-
dent experiments performed in duplicate. (B) [35S]-
GTPgS binding to rat frontal cortex membranes.
Data are the percentage of the maximal [35S]-GTPgS
binding stimulated by oxotremorine-M (mean pEC50
= 6.68 6 0.13, n = 3). OXO-M, oxotremorine-M.
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[3H]-GSK1034702 Binding. [3H]-GSK1034702 (specific activity 3.65
TBq/mmol) was synthesized by direct titration on Pd Black (performed by
Quotient Bioresearch, Manchester, UK). All experiments were performed
inassaybuffer of the following composition: 20mMHEPES, 100mMNaCl,
and 10 mM MgCl2, pH 7.5, and used 50 mg protein/well in a total assay
volume of 250 ml.
CHOcellmembranes overexpressinghumanM1mAChR (PerkinElmer)
were incubated with [3H]-GSK1034702 (20 nM) in the presence of
11 concentrations of test compound. All assay incubations were initiated
by the addition of membrane suspensions. Incubation was then carried
out for 4 hours at 21°C. Binding reactions were terminated by rapid
filtration through GF/A filters (PerkinElmer) presoaked with 0.5% (w/v)
polyethylenimine for 1 hour. Filterswere thenwashed six timeswith 1ml
ice-cold assay buffer. Dried filters were counted using Meltilex A
scintillant using a Trilux 1450 scintillation counter (PerkinElmer). The
specific bound counts (in disintegrations per minute) were expressed as a
percentage of the maximal binding observed in the absence of test
compound (total) and nonspecific binding determined in the presence of
100 mM nonradiolabeled GSK1034702.
Isolated Rat Atria and Ileum Contraction Experiments.
Adult Wistar rats were humanely euthanized and the left atria and
the ileum were placed in an organ bath containing oxygenated Tyrode
solution. Measurement of negative inotropic responses in atria or
contraction of ileum was performed as described by Lambrecht et al.
(1989). For atrial responses, ligands were administered for 5 minutes
at 32°C inMcEwen’s buffer (pH 7.4) in a bath volume of 10 ml. Agonist
responses were measured as negative inotropy relative to 1 mM
methacholine, and antagonism was measured as inhibition of meth-
acholine (1 mM)–induced negative ionotropic response. For rat ileum
experiments, ligands were administered for 5 minutes at 32°C in
Krebs’ buffer (pH 7.4) in a bath volume of 10 ml. Contraction of ileum
as a percentage of methacholine-induced contraction was measured,
and antagonistic effects weremeasured by inhibition of methacholine-
induced responses.
Data Analysis. Inhibition binding data were curve-fit using Graph-
Pad Prism 6 to derive the potency (IC50) of the test compound. The
equilibrium dissociation constant (KI) of the test compound was then
calculated with the Cheng–Prusoff equation: KI 5 IC50/[1 1 ([L]/KD)]
using the KD value derived separately from saturation binding studies.
Functional concentration-response curves were fitted according to a
four-parameter logistic equation (to determine minimum and maxi-
mum asymptotes, LogEC50, and slope; GraphPad Prism 6). For ACh
curves in the presence of multiple concentrations of GSK1034702 or
TBPB (after phenoxybenzamine treatment), the following form of the
Gaddum and Schild equations was applied globally to the datasets:
Y5Bottom1
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where top represents the maximal asymptote of the curves, bottom
represents theminimumasymptote of the curves, LogEC50 represents
the logarithm of the ACh EC50 in the absence of GSK1034702 or
TBPB, [A] represents the concentration of ACh, [B] represents the
concentration of GSK1034702 or TBPB, nH represents theHill slope of
the agonist curve, s represents the Schild slope for the antagonist, and
pA2 represents the negative logarithm of the concentration of
antagonist that shifts the agonist EC50 by a factor of 2. In the absence
of antagonist ([B] 5 0), this equation becomes the standard four-
parameter logistic equation for fitting agonist concentration-response
data.
[3H]-NMS binding interaction studies with benzyl quinolone car-
boxylic acid (BQCA) were fitted to an allosteric ternary complexmodel
(Leach et al., 2010):
Y5
Bmax½A
½A1
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KAKB
a’ ½B1KB
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½B
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where Bmax represents the total number of receptors; [A], [B], and [I]
are concentrations of radioligand, allosteric modulator, and orthos-
teric ligand, respectively; and KA, KB, and KI represent equilibrium
dissociation constants of radioligand, allosteric modulator, and
orthosteric ligand, respectively. a9 and a are the binding cooperativ-
ities between the allosteric modulator and radioligand and the
allosteric modulator and the orthosteric ligand, respectively. An a
value of .1 denotes positive cooperativity, a value of ,1 denotes
negative cooperativity, and a value of 1 denotes neutral cooperativity
of binding.
To assess agonist bias, the same concentration-response curves
were analyzed according to amodified form of the operational model of
agonism, recast to directly yield a transduction ratio (Log[t/KA]; van
der Westhuizen et al., 2014):
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where basal represents the response in the absence of agonist, Em
represents the maximal response of the assay system, KA represents
the equilibriumdissociation constant of the agonist, [A] represents the
concentration of agonist, t is an index of the coupling efficiency (or
efficacy) of the agonist, and n is the slope of the transducer function
linking agonist occupancy to response. For the analysis, all families of
agonist curves at each pathway were globally fitted to the model with
the parameters, basal, Em, and n shared between all agonists. For full
agonists, the LogKA was constrained to a value of zero, whereas for
TABLE 2
Maximum agonist effect and potency of ACh, xanomeline, GSK1034702,
and TBPB at stimulating IP1 accumulation in CHO Flp-In human M1
cells
Data are expressed as the means 6 S.E.M. of 3–10 independent experiments
performed in duplicate.
Compound
IP1
Emax pEC50 n
ACh 100 7.1 6 0.1 10
Xanomeline 98.0 6 1.5 8.2 6 0.1 3
GSK1034702 90.1 6 2.9 7.1 6 0.1 3
TBPB 55.2 6 3.1 7.6 6 0.2 4
Fig. 5. (A and B) GSK1034702 (A) or TBPB (B)
antagonism of ACh-stimulated IP accumulation in
CHO Flp-In cells expressing the humanM1 receptor.
Cells were incubated with 3 mM phenoxybenzamine
to irreversibly reduce receptor expression prior to
the addition of GSK1034702 or TBPB. Data are
expressed as the means 6 S.E.M. of three indepen-
dent experiments performed in duplicate.
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partial agonists this was directly estimated by the curve fitting pro-
cedure; the Log(t/KA) parameter was estimated as a uniquemeasure of
activity for each agonist. Agonist bias factors (10^DDLog[t/KA]) were
calculated as described in van der Westhuizen et al. (2014)).
Results
GSK1034702, TBPB, and Xanomeline Reverse
Scopolamine-Induced Deficits in Fear Conditioning. It
is well established that muscarinic receptor agonists and
PAMs can reverse deficits in learning and memory induced
by the administration of a broad-spectrum muscarinic antag-
onist such as scopolamine (Young et al., 1995; Ma et al., 2009).
Here, doses of scopolamine above 1 mg/kg administered to
mice 30 minutes prior to fear conditioning training were
sufficient to induce a significant reduction in contextual fear
conditioning learning and memory (Supplemental Fig. 1). The
effects of muscarinic receptor agonists on this deficit were
tested by the coadministration of scopolamine (1.5mg/kg) with
escalating intraperitoneal doses of xanomeline (Fig. 1A),
GSK1034702 (Fig. 1B), or TBPB (Fig. 1C). All three agents
significantly improved learning and memory compared with
vehicle controls (5% glucose solution in double distilled water)
(P , 0.05 vs. administration of 1.5 mg/kg scopolamine alone;
one-way analysis of variance with the Tukey multiple com-
parisons test). Free brain concentrations of xanomeline and
GSK1034702 determined 30 minutes after administration
were seen to increase linearly with escalating doses (Fig. 1,
D and E). In contrast, the effects of these compounds on
learning and memory were bell shaped, with lower doses
improving learning and memory and high doses showing
reduced effect (Fig. 1, A and B). This bell-shaped response is
characteristic of procognitive agents. Interestingly, brain
exposure of TBPB could not be increased beyond that observed
at 10 mg/kg, remaining relatively low even after intraperito-
neal injection of higher doses (Fig. 1F). This resulted in TBPB
effects on learning and memory being similar at both low and
high-administered doses with no evidence of a bell-shaped
dose response (Fig. 1C).
GSK1034702 and TBPB Interact Competitively with
[3H]-NMS at M1 mAChRs. GSK1034702 and TBPB have
previously been described as allosteric agonists of the M1
mAChR (Jones et al., 2008; Budzik et al., 2010; Nathan et al.,
2013). To test this assertion, [3H]-NMS binding studies were
conducted on monolayers of CHO Flp-In cells expressing the
human M1 mAChR to determine the nature of their interac-
tion at the receptor. Both GSK1034702 and TBPB fully
inhibited binding of [3H]-NMS (0.5 nM) to M1 mAChRs, with
estimated pKi values of 6.5 6 0.2 and 6.8 6 0.1, respectively,
and in a similarmanner to the orthosteric agonist, xanomeline
(Fig. 2; Table 1). These data suggest that GSK1034702, in
contrast to the allosteric mechanism of action previously
reported, binds instead in a competitive manner consistent
with interaction at the orthosteric site of the M1 mAChR.
GSK1034702 and TBPB Do Not Alter [3H]-NMS
Dissociation Kinetics. As allosteric ligands with high nega-
tive cooperativity can still fully inhibit orthosteric ligand
binding, kinetic binding experiments were performed to probe
any allosteric interactions of GSK1034702 or TBPB with the
M1 mAChR. Membranes of CHO Flp-In cells expressing the
humanM1mAChRwere pre-equilibrated with [
3H]-NMS, and
bound radioligand dissociated from the receptor with atropine
(10 mM) with a rate constant of koff5 0.1886 0.009 minute
21.
The presence of either GSK1034702 (10 mM) or TBPB (10 mM)
had no effect on the [3H]-NMS dissociation rate (Fig. 3). These
data further argue against an allosteric mode of action of
GSK1034702 at M1 mAChRs as previously reported (Nathan
et al., 2013).
Receptor Alkylation Studies Establish Orthosteric
Binding of GSK1034702. GSK1034702 activity in IP1 accu-
mulation assays was compared with ACh, xanomeline, and
TBPB (Fig. 4A; Table 2). GSK1034702 stimulated robust
increases in IP1 accumulation, reaching approximately 90%
of the maximal response elicited by ACh, with nanomolar
potency (pEC50 5 7.1 6 0.1; Fig. 4A). TBPB behaved as a
partial agonist with a modest increase in potency relative to
GSK1034702 (pEC50 5 7.6 6 0.2). In membranes prepared
from the rat cortex, GSK1034702 is a partial agonist with
respect to Gaq protein coupling, stimulating approximately
37% of the maximum [35S]-GTPgS Gaq binding elicited by the
full agonist oxotremorine-M (pEC50 5 6.7 6 0.1; Fig. 4B).
To verify the mechanism of action, we performed receptor
alkylation experiments with the orthosteric site covalent
binder, phenoxybenzamine, to deplete the level of available
TABLE 3
Potency estimates of the antagonism of ACh-stimulated IP1 accumulation
by GSK1034702 or TBPB in CHO Flp-In cells expressing the human M1
mAChR
Data are the means 6 S.E.M. of three independent experiments performed in
duplicate.
Parameter GSK1034702 TBPB n
pA2 6.2 6 0.2 7.0 6 0.1 3
Schild slope 1.1 6 0.1 1.2 6 0.1 3
Fig. 6. (A–C) Displacement of [3H]-NMS binding by ACh (A), GSK1034702 (B), or TBPB (C) in the presence of increasing concentrations of BQCA at the
humanM1mAChR expressed in CHO Flp-In cell monolayers. Experiments were performed against aKD concentration of [
3H]-NMS. Nonspecific binding
was determined by the addition of 10 mM atropine. Data are expressed as the means6 S.E.M. of three independent experiments performed in duplicate.
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and functional muscarinic receptors. Phenoxybenzamine, at a
concentration of 3 mM (for 30 minutes), reduced the functional
human M1 mAChR population in CHO Flp-In cells by approx-
imately 80%, to an expression level where GSK1034702 had no
agonist effect in an IP1 accumulation assay but where ACh still
yielded a response (Supplemental Fig. 2, A and B). Under these
conditions, establishing whether GSK1034702 and TBPB acted
as competitive antagonists with respect to ACh would verify the
interaction of these compounds with the orthosteric site.
In phenoxybenzamine-treated cells, GSK1034702 caused
a concentration-dependent, parallel rightward shift in ACh-
stimulated IP1 accumulation (Fig. 5A) consistent with a com-
petitive antagonist. This effect was similar to that of TBPB
(Fig. 5B), which was reported previously to act as a compet-
itive antagonist in a similar preparation (Keov et al., 2013).
Analysis of these data using a modified form of the Gaddum
and Schild equations yielded Schild slopes approximating to
unity and pA2 values of 6.26 0.2 and 7.06 0.1 for GSK1034702
and TBPB antagonism of ACh-stimulated responses, respec-
tively (Table 3).
The Prototypical PAM, BQCA, Potentiates ACh, But
Not GSK1034702 Affinity. Having established that
GSK1034702 interacts competitively with ACh at the orthos-
teric site, radioligand binding experiments were designed to
establish whether the mode of GSK1034702 binding at the
orthosteric pocket was equivalent to ACh. In these studies, the
potentiation of orthosteric agonist binding by a PAM was used
to probe the nature of GSK1034702 and TBPB binding. BQCA,
a PAM selective for theM1mAChR, has previously been shown
to potentiate ACh affinity by approximately 100-fold (Ma et al.,
2009; Butcher et al., 2016). Consistent with these previous
studies, we show here that BQCA potentiates the ACh-
mediated displacement of [3H]-NMS, thereby demonstrat-
ing positive cooperativity for ACh binding of approximately
35-fold, consistent with previous reports of modulation
according to a two-state model (Canals et al., 2012; Fig.
6A). Such actions would predict a similar (if less sub-
stantial) effect on GSK1034702 or TBPB. However, the
displacement of [3H]-NMS by GSK1034702 (Fig. 6B) or
TBPB (Fig. 6C) was not modulated by BQCA. These data
demonstrate the probe dependency of BQCA and indicate
that either: 1) there is neutral cooperativity between
BQCA and GSK1034702/TBPB, or 2) that the binding site
of GSK1034702 or TBPB simultaneously overlaps with
those of both ACh and BQCA.
[3H]-GSK1034702 Binding Studies Further Confirm
Novel Orthosteric Binding Pose. To further characterize
the binding site of GSK1034702 at the M1 mAChR, we
generated a radiolabeled version of the GSK1034702 com-
pound ([3H]-GSK1034702) and conducted binding interac-
tion experiments in membranes expressing the human M1
mAChR. [3H]-GSK1034702 bound in a monophasic manner
with moderate affinity (KD 5 550 nM; Bmax 5 2.6 pmol/mg
protein) (Supplemental Fig. 3, A–C). Membranes were incu-
bated with 20 nM [3H]-GSK1034702 in the absence and pres-
ence of increasing concentrations of unlabeled GSK1034702,
TBPB, ACh, and xanomeline (Fig. 7). GSK1034702 and TBPB
fully displaced specific [3H]-GSK1034702 binding to the M1
mAChR in amonophasicmanner,whereasAChand xanomeline
only partially displaced [3H]-GSK1034702 binding. These data
indicate either an allosteric interaction between GSK1034702
and ACh/xanomeline or a bitopic mechanism consistent with
GSK1034702 spanning a binding pocket at the M1 mAChR
partially shared with that of ACh.
DREADD Pharmacology Confirms an Atypical Mech-
anism of Action of GSK1034702. By introducing point
mutations (Y106C and A196G) into the orthosteric binding
pocket of the M1 mAChR, an M1 DREADD mutant is created
(Abdul-Ridha et al., 2013) that displays reduced responsive-
ness to ACh but instead is activated by clozapine-N-oxide, a
ligand that shows little activity at the wild-type M1 mAChR.
We investigated the ability of GSK1034702 to interact with
the M1 DREADD by conducting [
3H]-NMS binding, func-
tional IP1 accumulation, and ERK1/2 phosphorylation stud-
ies in CHO Flp-In cells expressing the humanized M1
DREADD (Figs. 8 and 9; Supplemental Tables 1 and 2).
The affinity of GSK1034702 for the M1 DREADD was not
significantly different from the affinity for binding at the
Fig. 7. Displacement of [3H]-GSK1034702 binding by ACh, xanomeline,
GSK1034702, or TBPB at membranes expressing the human M1 mAChR.
Experiments were performed against 20 nM [3H]-GSK1034702 and non-
specific binding was determined in the presence of 100 mM nonradiola-
beled GSK1034702. Data are expressed as the means 6 S.E.M. of three
independent experiments performed in duplicate.
Fig. 8. (A) Displacement of [3H]-NMS binding by
ACh, CNO, xanomeline, GSK1034702, or TBPB at
the humanized M1 DREADD expressed in CHO
Flp-In cell monolayers. Experiments were performed
against a KD concentration of [
3H]-NMS. Nonspecific
binding was determined by the addition of 10 mM
atropine. Data are expressed as the means6 S.E.M.
of three to five independent experiments performed
in duplicate. (B) Comparison of pKi values for each of
the compounds used at the wild-type M1 mAChR or
the mutant M1 DREADD. CNO, clozapine-N-oxide;
WT, wild type.
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wild-type M1 mAChR (pKi 5 6.5 6 0.2 and 6.0 6 0.2 for the
wild type and DREADD, respectively; Fig. 8). In addition, as
reported previously (Armbruster et al., 2007; Abdul-Ridha
et al., 2013), M1 mAChR orthosteric agonists, ACh and
xanomeline, showed a significant reduction in potency at the
M1 DREADD (Fig. 9). In contrast, GSK1034702 activated
the M1 DREADD with comparable potency and efficacy
compared with its activity at the wild-type receptor. Similar
Fig. 9. (A–E) IP accumulation (left) or ERK1/2 phosphor-
ylation (right) elicited by ACh (A), xanomeline (B), CNO
(C), GSK1034702 (D), or TBPB (E) via the humanized M1
DREADD expressed in CHO Flp-In cells. The dashed
curve represents the response of the ligand at the wild-
type M1 mAChR. Data are expressed as the means 6 S.E.
M. of three to four independent experiments performed in
duplicate. CNO, clozapine-N-oxide; PI, phosphoinositide.
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results were obtained with TBPB, confirming previous
observations for this compound (Abdul-Ridha et al., 2014)
(Fig. 9, D and E). Furthermore, we assessed the ability of
ACh and GSK1034702 to stimulate phosphorylation of the
M1 mAChR at serine 228 using a phosphorylation-specific
antibody (Butcher et al., 2016). Both ACh and GSK1034702
stimulated a concentration-dependent increase in pSer228 im-
munoreactivity at thewild-type receptor (Fig. 10). The potency of
GSK1034702 to stimulate phosphorylation at serine 228 was
unchanged at theM1DREADD,whereas ACh failed to stimulate
a response. These data support the notion that GSK1034702 has
a distinct binding mode at the orthosteric site from that of ACh.
GSK1034702 and TBPB Are Differentially Biased
Agonists at M1 mAChR. Convergent evidence from radio-
ligand binding and functional studies (vide supra and Sup-
plemental Fig. 4; Supplemental Table 3) suggests that
GSK1034702 and TBPB bind to the orthosteric site of the
M1mAChR, but with an orientation or pose that distinguishes
them from ACh and xanomeline. To further interrogate their
pharmacology, we assessed their ability to engender biased
signaling by application of an operational model of agonism to
the concentration-response curves of either xanomeline,
GSK1034702, or TBPB in both IP1 and ERK1/2 phosphoryla-
tion assays (Evans et al., 2011; Keov et al., 2011; Kenakin
et al., 2012) (Table 4). These analyses generated transduction
coefficient values for each of these agonists at the two different
pathways and allowed us to calculate the bias factor between
IP1 and ERK1/2 phosphorylation, revealing significant dif-
ferences between ACh and xanomeline/TBPB (P , 0.001;
one-way analysis of variance), with the latter displaying bias
toward IP1 responses (bias factor IP1 2 ERK1/2 phosphory-
lation5 1.1 and 1.4 for xanomeline and TBPB, respectively).
However, no significant differences were revealed for
GSK1034702 and ACh, suggesting that GSK1034702 and
TBPB, despite apparently similar binding modes, engender
differential signaling from the receptor.
Fig. 10. (A) Phosphorylation at serine 228 elicited byACh (left) orGSK1034702 (right) inCHOFlp-In cells expressing eitherM1WT (top) orM1DREADD
(bottom). (B)Mean densitometric data showing phosphorylation at serine 228 as a percentage of themaximal response. Data were normalized to the total
receptor expression, assessed using an HA antibody. Data are expressed as the means6 S.E.M. of three independent experiments. HA, hemagglutinin;
WT, wild type.
TABLE 4
Transduction coefficients [Log10(t/KA)], normalized (reference ligand ACh) transduction coefficients
[DLog10(t/KA)], and bias factors [DDLog10(t/KA)] for IP1 accumulation and phosphorylation of ERK1/2 at
the wild-type M1 mAChR
Compound
IP1 Accumulation ERK1/2 Phosphorylation Log Bias Factor IP1 – ERK1/2
Log10(t/KA) DLog10(t/KA) Log10(t/KA) DLog10(t/KA) DDLog10(t/KA)
ACh 7.10 6 0.1 0.0 6 0.1 7.1 6 0.0 0.0 6 0.0 0.0 6 0.1
Xanomeline 8.2 6 0.1 1.1 6 0.1 7.1 6 0.3 0.0 6 0.3 1.1 6 0.1
GSK1034702 7.4 6 0.2 0.3 6 0.2 7.2 6 0.1 0.1 6 0.1 0.2 6 0.2
TBPB 8.2 6 0.2 1.1 6 0.2 6.9 6 0.4 20.3 6 0.4 1.4 6 0.2
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GSK1034702 Shows a Lack of Selectivity for M1
mAChRs. We evaluated the ability of GSK1034702 to bind
to other mAChR subtypes by conducting equilibrium-binding
studies on membranes expressing the M1, M2, M3, M4, or
M5 mAChR, and we found that GSK1034702 could inhibit
[3H]-NMS binding at all muscarinic receptor subtypes, albeit
with much lower affinity for the M3 mAChR (Fig. 11A; Table 5).
We further assessed the functional activity of GSK1034702 at the
M2, M3, M4, and M5 mAChRs in the ERK1/2 phosphorylation
assay. GSK1034702 exhibited partial agonist activity at M2, M4,
and M5 mAChRs but was devoid of activity at the M3 mAChR
in this assay (Fig. 11B). Finally, we investigated the ability of
GSK1034702 to stimulate negative inotropic responses in isolated
rat atria (Fig. 12, A and B) or contraction of rat ileum (Fig. 12, C
andD), indicative of activity atM2 andM3mAChRs, respectively.
GSK1034702 elicited a robust response in the rat atria, reaching a
maximal response equivalent to that of methacholine, with
micromolar potency (Fig. 12A). Furthermore, GSK1034702 could
inhibitmethacholine-induced responseswith an IC50 of 8mM(Fig.
12B). In the rat ileum, GSK1034702 stimulated approximately
50% of the maximal methacholine-induced contraction, with an
EC50 of 7 mM (Fig. 12C), and inhibited methacholine-induced
contraction with an IC50 of 46 mM (Fig. 12D).
Discussion
The development of the selective M1 mAChR allosteric agonist
GSK1034702 provided the opportunity to test the hypoth-
esis that allosteric M1 mAChR drugs might provide a
clinical advantage over orthosteric M1 mAChR agents due
to increased selectivity while yielding fewer side effects. In
the nicotine abstinence model of cognitive dysfunction,
GSK1034702 significantly improved immediate memory
recall but also induced adverse responses consistent with
activation of other muscarinic receptor subtypes (Nathan
et al., 2013). At first glance, these data might suggest that
allosteric M1 mAChR drugs offer little or no safety benefit
compared with previous investigational agents targeting
mAChRs. However, here we provide direct pharmacologi-
cal evidence that GSK1034702 is not a pure allosteric
agonist as previously reported, but rather interacts with
the orthosteric binding site and broadly mimics the phar-
macology of the known bitopic ligand, TBPB. Based on
radioligand binding and functional studies, coupled with
the structural similarity between GSK1034702 and TBPB,
we conclude that GSK1034702 likely interacts concomi-
tantly with both allosteric and orthosteric sites on the M1
mAChR in a bitopic manner.
The conclusion that GSK1034702 interacts with the orthos-
teric site is primarily based on the full inhibition of [3H]-NMS
binding and a lack of cooperative effects on [3H]-NMS, features
consistent with an orthosteric rather than prototypical allo-
steric mechanism. In functional assays after receptor alkyl-
ation (to diminish its agonist response), GSK1034702 causes a
nonsaturable, concentration-dependent parallel rightward
shift in the ACh-mediated IP response, further confirming
an orthosteric mode of action.
That GSK1034702 might also interact with a site distinct
from the orthosteric sitewas indicatedmost clearly in functional
assays at the M1 mAChR DREADD and by characterizing the
binding of [3H]-GSK1034702 to the wild-type receptor. The M1
mAChR DREADD contains mutations at key residues within
the orthosteric binding pocket, which yields a receptor that is
poorly responsive to the cognate ligand, ACh, but instead is
activated by an otherwise inert chemical ligand, clozapine-n-
oxide (Armbruster et al., 2007; Roth, 2016). As predicted from
previous reports (Abdul-Ridha et al., 2014), the potencies of
orthosteric ligandsAChandxanomeline in IP signaling, ERK1/2
phosphorylation, and M1 receptor phosphorylation were signif-
icantly reduced at the M1 DREADD. However, the potency and
efficacy of GSK1034702 and TBPB was unaffected by the
DREADDmutations, suggesting that GSK1034702, like TBPB,
is able to activate the M1 mAChR with a binding mode that is
subtly distinct from that of prototypical orthosteric ligands. In
support of this conclusion, GSK1034702 and TBPB fully inhibit
the binding of [3H]-GSK1034702 to theM1mAChR,whereas the
prototypical orthosteric agonists, ACh and xanomeline, only
partially inhibit its binding. This indicates that GSK1034702
can still bind to theM1mAChRwhenACh or xanomeline occupy
the orthosteric site, suggesting that it can interact with the
receptor via an allosteric binding site. The display of apparently
both orthosteric (competitive) and allosteric behaviors depend-
ing on test system is typical of bitopic ligands that are able to
“flip-flop” between binding poses (Valant et al., 2012).
Fig. 11. (A) Displacement of [3H]-NMS binding by
GSK1034702 in CHOmembranes expressingM1,M2,
M3, M4, or M5 mAChRs. Experiments were per-
formed against a KD concentration of [
3H]-NMS.
Nonspecific binding was determined by the addition
of 10 mM atropine. Data are expressed as the means
6 S.E.M. of three independent experiments. (B)
ERK1/2 phosphorylation elicited by GSK1034702 at
the M1, M2, M3, M4, or M5 mAChR expressed in CHO
cells. Data are expressed as a percentage of the
maximum response stimulated by ACh and are the
means 6 S.E.M. of three experiments performed in
duplicate.
TABLE 5
Negative logarithms of the equilibrium dissociation constant (pKi) of
GSK1034702 binding to M1–M5 mAChRs
Data are calculated from the means 6 S.E.M. of three independent experiments
performed in duplicate.
mAChR subtype pKi n
M1 6.0 6 0.1 3
M2 5.4 6 0.1 3
M3 n.d. 3
M4 5.7 6 0.1 3
M5 5.2 6 0.1 3
n.d., not determined.
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Greater clarity around the receptor mechanism of action of
GSK1034702, revealed here, has implications for drug design
aimed at the treatment of AD. We have previously demon-
strated that the learning and memory deficit observed in
murine prion disease is due to a loss of cholinergic signaling in
the hippocampus and as such, this model replicates one of the
key pathologic hallmarks associated with human AD (Bradley
et al., 2017). In the prion model, we found that both M1
mAChR orthosteric agonists and allosteric modulators com-
pletely rescue the learning and memory deficit observed in
prion disease. However, we also found that the orthosteric
ligand, xanomeline, gave adverse responses consistent with
the activation of other muscarinic receptor subtypes, whereas
the PAM, BQCA, gave no detectable adverse responses at
doses that rescued learning andmemory (Bradley et al., 2017).
Although these results together with other studies on the
cognitive responses of M1 mAChR allosteric modulators (Ma
et al., 2009; Lange et al., 2015; Puri et al., 2015; Vardigan
et al., 2015) support the potential clinical benefit of this class
of ligand, it is also clear that allosteric modulators that show
direct agonism in addition to cooperativity in rodent models
result in adverse effects (Alt et al., 2016; Davoren et al., 2016,
2017). Hence, we conclude here that to avoid adverse effects,
clinical candidates targeting the M1 mAChR in AD would
require the following properties: 1) high levels of receptor
subtype selectivity as would be seen with an allosteric
modulator and 2) low levels of intrinsic agonist activity.
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